Main Products / Services / Pipelines & Platforms
[Oral Mucositis Management and Transmucosal Drug Delivery System] Oral Mucositis, a common side effect of cancer treatment, presents as severe oral ulcers, causing extreme pain and impeding life-saving cancer therapies. Moleculex has secured the Taiwanese medical device license for the world's first large-area patch wound dressing for oral mucosa, utilizing the unique MuCover® mucosal adhesion technology.
MuCover® Bioadhesive Technology lies at the heart of oral wound dressings, facilitating quick and stable adhesion to moist tissues surfaces. Moleculex provides MuCover® Tape, a mucoadhesive tape, and MuCoat® Glue, a bio-adhesive.
MuCover® currently serves as a Trans-Mucosal Drug Delivery system, overcoming challenges associated with oral dosage forms, such as the First-Pass Effect, offering faster and more effective drug delivery. In comparison to injectable forms, it is more convenient and safer, enabling prolonged drug release in specific local tissue areas, suitable for formulations containing amino acids, vitamins, plant extracts, and other API.
Business Interests
▪ Out-Licensing of Mucover Intra-Oral Patch for Oral Mucositis ▪ Out-Licensing of Mucoat Oral Rinse for Oral Mucositis ▪ Cooperation on Transmucosal Drug Delivery R&D ▪ Distribution Partnership (Marketing Authorization Holder) ▪ Seeking a $1 million investment for pivotal post-market clinical trials.
Contact Info
Shaun Liao
CEO
+886-918-768-169
SYL@moculex.com